论文部分内容阅读
哈医大遗传学教研室周春水课题组联合美国哈佛医学院专家在一项基础医学研究中,发现PDCD4蛋白表达水平与紫杉醇的敏感性呈正相关,由此为紫杉醇的个体化用药提供了精确指标。相关学术论文在线发表最新一期美国《蛋白组学研究杂志》上。这是记者5月13日从哈医大获悉的。作为一种常用的一线抗癌药物,紫杉醇由于其独特的抗癌机制,被临床用于治疗乳腺癌、卵巢癌、非小细胞肺癌等首选药物。但目前还缺乏预测和指导紫杉醇个体化用药的有效参考指标,对病人的用药缺乏针对性,其疗效也难以预测。
Harvard University Department of Genetics Zhou Chunshui task force combined with the United States Harvard Medical School experts in a basic medical research found that PDCD4 protein expression levels and paclitaxel sensitivity was positively correlated, thus paclitaxel individualized medication provides accurate indicators. Relevant academic papers online the latest issue of the United States, “Proteomics Research Magazine”. This is a reporter learned from Kazakhstan Medical University on May 13. As a commonly used first-line anti-cancer drug, paclitaxel is clinically used as the first choice drug for breast cancer, ovarian cancer and non-small cell lung cancer because of its unique anticancer mechanism. However, there is still a lack of effective reference indicators for predicting and guiding the individualized use of paclitaxel. The lack of pertinence to the patient’s medication and the curative effect thereof are unpredictable.